Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Form 8.5 (EPT/NON-RI)

10 Mar 2025 09:30

RNS Number : 9993Z
Cavendish Securities PLC
10 March 2025
 

FORM 8.5 (EPT/NON-RI)

 

 

 

 

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Cavendish Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Tissue Regenix Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Tissue Regenix Group Plc

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

07/03/2025

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

ORD 0.1P

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

102044

 

0.14

 

 

 

 

 

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

102044

 

0.14

 

 

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

ORD 0.1P

ORD 0.1P

 

 

 

 

 

 

Purchases

Sales

34760

10068

 

 

 

 

 

 

 

 

 

41.2

44.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

41.2

42.75

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

10/03/2025

Contact name:

Umika Patel

Telephone number:

0207 220 0594

 

 

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEOURUKRVKUOARR
Date   Source Headline
30th Mar 20207:00 amRNSUpdate in relation to working capital position
20th Mar 20207:00 amRNSDirectorate Change
6th Feb 20207:15 amEQSHardman & Co Research: Tissue Regenix (TRX): Restructured to satisfy product demand
4th Feb 202011:47 amRNSResolution of Cyber Security Incident
28th Jan 202010:02 amRNSNotice of cyber security incident
22nd Jan 20207:00 amRNSTrading Update
14th Jan 20204:40 pmRNSSecond Price Monitoring Extn
14th Jan 20204:35 pmRNSPrice Monitoring Extension
21st Nov 20194:35 pmRNSPrice Monitoring Extension
18th Nov 20194:03 pmRNSDirectorate Change
14th Nov 20194:00 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSUpdated loan facility agreement with MidCap
13th Nov 20193:35 pmRNSHolding(s) in Company
13th Nov 20193:17 pmRNSHolding(s) in Company
11th Nov 20192:05 pmRNSSecond Price Monitoring Extn
11th Nov 20192:00 pmRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSUpdate in relation to loan facility
17th Oct 20194:27 pmRNSHolding(s) in Company
17th Oct 20197:00 amRNSTrading Update
15th Oct 20193:27 pmRNSHolding(s) in Company
3rd Oct 20197:00 amRNSDermaPure Product Line Extension Launched
10th Sep 20197:00 amRNSUnaudited Interim Results
28th Aug 20197:00 amRNSAppointment of CFO
15th Aug 20197:00 amRNSAdditional manufacturing capacity secured
1st Aug 20197:00 amRNSDirectorate Change
8th Jul 20195:03 pmRNSHolding(s) in Company
20th Jun 20192:23 pmEQSHardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021
7th Jun 20192:55 pmRNSIssue of Equity and Total Voting Rights
4th Jun 20197:00 amRNSNotice of AGM
4th Jun 20197:00 amRNSSecures Credit Facilities of up to $20m
4th Jun 20197:00 amRNSAnnual Results for the year ended 31 December 2018
21st May 20197:00 amRNSCEO to return to full time duties
10th Apr 20197:20 amEQSHardman & Co Research: Tissue Regenix (TRX): Expanded GPO coverage secured
4th Apr 20197:26 amRNSExpands US GPO coverage for DermaPure
18th Feb 20197:00 amRNSChange of Adviser
6th Feb 201911:05 amRNSSecond Price Monitoring Extn
6th Feb 201911:00 amRNSPrice Monitoring Extension
4th Feb 20197:00 amRNSTrading Update
17th Dec 201811:56 amEQSHardman & Co Research: Tissue Regenix (TRX): 2018 in review: foundations laid for osteobiologics
6th Dec 20187:00 amRNSInterim Management Change
13th Nov 20187:00 amRNSPan European distribution agreement with Arthrex
29th Oct 20187:00 amRNSGareth Jones commences position as CFO
14th Sep 20187:16 amEQSHardman & Co Research: Tissue Regenix (TRX): Strategy delivering growth above expectations
3rd Sep 20187:00 amRNSUnaudited Interim Results
2nd Aug 201810:10 amEQSHardman & Co Research: Tissue Regenix (TRX): 1H'18 preview: organic plus inorganic growth
2nd Aug 20187:00 amRNSNotice of Interim Results
4th Jul 20187:00 amRNSAppointment of CFO
25th Jun 20187:00 amRNSHTA License granted and UK distribution Agreement
21st Jun 20187:10 amRNSTRX BioSurgery wins GPO Supplier Horizon Award
18th Jun 20187:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.